Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2009 (2009), Article ID 187125, 4 pages
http://dx.doi.org/10.1155/2009/187125
Clinical Study

Complex Variant t(9;22) Chromosome Translocations in Five Cases of Chronic Myeloid Leukemia

1Department of Hematology, La Fe University Hospital, 46009 Valencia, Spain
2Molecular Biology Laboratory, Department of Medical Biopathology, La Fe University Hospital, 46009 Valencia, Spain
3Department of Hematology, Hospital General Universitario de Valencia, 46014 Valencia, Spain

Received 27 March 2009; Revised 2 June 2009; Accepted 10 June 2009

Academic Editor: Connie J. Eaves

Copyright © 2009 Ana Valencia et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Faderl, M. Talpaz, Z. Estrov et al., “The biology of chronic myeloid leukemia,” The New England Journal of Medicine, vol. 341, pp. 164–172, 1999. View at Google Scholar
  2. C. L. Sawyers, “Chronic myeloid leukemia,” The New England Journal of Medicine, vol. 340, pp. 1330–1340, 1999. View at Google Scholar
  3. J. L. Huret, “Complex translocations, simple variant translocations and Ph-negative cases in chronic myelogenous leukaemia,” Human Genetics, vol. 85, no. 6, pp. 565–568, 1990. View at Google Scholar
  4. ISCN, “Guidelines for Cancer Cytogenetics. Supplement to: An International System for Human Cytogenetic Nomenclature,” L. G. Shaffer and N. Tommerup, Eds., Karger, Basel, Switzerland, 2005. View at Google Scholar
  5. P. Bolufer, G. F. Sanz, E. Barragán et al., “Rapid quantitative detection of BCR-ABL transcripts in chronic myeloid leukemia patients by real-time reverse transcriptase polymerase-chain reaction using fluorescently labeled probes,” Haematologica, vol. 85, no. 12, pp. 1248–1254, 2000. View at Google Scholar
  6. N. C. P. Cross, T. P. Hughes, L. Feng et al., “Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: correlations with acute graft-versus-host disease and relapse,” British Journal of Haematology, vol. 84, no. 1, pp. 67–74, 1993. View at Google Scholar
  7. F. Mitelman, Ed., ISCN: Guidelines for Cancer Cytogenetics. Supplement to an International System for Human Cytogenetic Nomenclature, Karger, Basel, Switzerland, 1995.
  8. M. M. T. El-Zimaity, H. Kantarjian, M. Talpaz et al., “Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome,” British Journal of Haematology, vol. 125, no. 2, pp. 187–195, 2004. View at Publisher · View at Google Scholar
  9. B. Johansson, T. Fioretos, and F. Mitelman, “Cytogenetic and molecular genetic evolution of chronic myeloid leukemia,” Acta Haematologica, vol. 107, no. 2, pp. 76–94, 2002. View at Publisher · View at Google Scholar
  10. S. Marktel, D. Marin, N. Foot et al., “Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression,” Haematologica, vol. 88, no. 3, pp. 260–267, 2003. View at Google Scholar
  11. P. B. Sinclair, E. P. Nacheva, M. Leversha et al., “Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia,” Blood, vol. 98, no. 9, pp. 2879–2880, 2001. View at Google Scholar
  12. A. Quintas-Cardama, H. Kantarjian, M. Talpaz et al., “Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia,” Blood, vol. 105, no. 6, pp. 2281–2286, 2005. View at Publisher · View at Google Scholar